Medico Remedies is currently trading at RS. 54.74, up by 1.52 points or 2.86% from its previous close of RS. 53.22 on the BSE.

The stock opened at RS. 52.20 and has recorded a high and low of RS. 54.74 and RS. 52.20 respectively. A total of 6018 shares have been traded so far.

Classified under BSE group 'B', the stock has a face value of RS. 2 and has touched a 52-week high of RS. 79.78 on February 6, 2025, and a 52-week low of RS. 35.00 on June 5, 2024. Over the past week, the scrip has traded between RS. 56.00 and RS. 50.33. The company currently holds a market capitalization of RS. 453.26 crore.

The promoter shareholding stands at 63.79%, while institutional and non-institutional investors hold 0.13% and 36.08% respectively.

Medico Remedies has commenced the construction of a new manufacturing facility for producing B lactam tablets, capsules, dry syrups, and injections, including formulations like amoxycillin and clavulanic acid. The upcoming plant will have a production capacity of 25 million tablets, 45 million capsules, 10 million dry syrups, and 10 million injectables. The total investment for this expansion is estimated at RS. 30 crore, and the full capacity is expected to be operational within 2 years.

The facility is being developed in accordance with PIC/S (Pharmaceutical Inspection Co-operation Scheme) guidelines and is projected to add approximately RS. 25 crore in annual revenue upon receiving all necessary approvals.

Medico Remedies is a prominent manufacturer and exporter of pharmaceutical formulations such as tablets, capsules, and suspensions.